Clinical Trials Logo

Clinical Trial Summary

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with levofloxacin in participants with complicated urinary tract infections (cUTI).


Clinical Trial Description

This study began with a 3-arm Lead-in portion to determine the oral (PO) dosing (200 or 250 milligrams [mg]) of eravacycline to be used with intravenously (IV) administered eravacycline for the Pivotal portion (2 arms). A PO dose of 200 mg was selected based on the unblinded Lead-in analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01978938
Study type Interventional
Source La Jolla Pharmaceutical Company
Contact
Status Completed
Phase Phase 3
Start date October 6, 2014
Completion date August 21, 2015